Equillium, Inc.EQEarnings & Financial Report
Equillium, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory diseases with high unmet medical needs. It advances pipeline candidates targeting immune system dysregulation, primarily catering to patients and healthcare providers across the United States.
Revenue
$9.2M
Gross Profit
N/A
Operating Profit
$-3.2M
Net Profit
$-2.3M
Gross Margin
N/A
Operating Margin
-34.7%
Net Margin
-25.4%
YoY Growth
N/A
EPS
$-0.06
Equillium, Inc. Q4 FY2023 Financial Summary
Equillium, Inc. reported revenue of $9.2M for Q4 FY2023, with a net profit of $-2.3M (down 184.5% YoY) (-25.4% margin).
Key Financial Metrics
| Total Revenue | $9.2M |
|---|---|
| Net Profit | $-2.3M |
| Gross Margin | N/A |
| Operating Margin | -34.7% |
| Report Period | Q4 FY2023 |
Equillium, Inc. Annual Revenue by Year
Equillium, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $41.1M).
| Year | Annual Revenue |
|---|---|
| 2024 | $41.1M |
| 2023 | $36.1M |
Equillium, Inc. Quarterly Revenue & Net Profit History
Equillium, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2024 | $4.4M | -52.3% | $-5.8M | -131.9% |
| Q3 FY2024 | $12.2M | +37.1% | $-7.0K | -0.1% |
| Q2 FY2024 | $13.9M | +51.8% | $468.0K | 3.4% |
| Q1 FY2024 | $10.7M | +20.4% | $-2.7M | -25.6% |
| Q4 FY2023 | $9.2M | — | $-2.3M | -25.4% |
| Q3 FY2023 | $8.9M | — | $-3.7M | -41.8% |
| Q2 FY2023 | $9.1M | — | $-3.3M | -36.6% |
| Q1 FY2023 | $8.9M | — | $-3.9M | -44.4% |
Income Statement
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.9M | $9.1M | $8.9M | $9.2M | $10.7M | $13.9M | $12.2M | $4.4M |
| YoY Growth | N/A | N/A | N/A | N/A | 20.4% | 51.8% | 37.1% | -52.3% |
Balance Sheet
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $71.8M | $58.8M | $55.2M | $50.5M | $43.6M | $42.9M | $34.5M | $25.6M |
| Liabilities | $42.5M | $31.8M | $31.1M | $28.0M | $22.5M | $20.4M | $11.3M | $6.5M |
| Equity | $29.3M | $27.0M | $24.1M | $22.6M | $21.1M | $22.4M | $23.2M | $19.1M |
Cash Flow
| Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.0M | $-6.2M | $-1.9M | $-5.7M | $-8.8M | $730000 | $-7.7M | $-3.3M |